Visit
The 17th St. Gallen International Breast Cancer Conference was held virtually this year due to the ongoing COVID-19 pandemic. Although the meeting was virtual, the programme was full of the latest data, ongoing controversies in the field, and updates on potential new treatments for breast cancer, culminating in the renowned St Gallen International Consensus on the Optimal Primary Treatment of Women with Breast Cancer 2021.
BCC 2021
🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals
Watch: 👉http://ow.ly/LwxB50LQ3p0👈
@UKONSmember #UKONS2022 #Nursing #OncologyNursing
🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?
IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.
💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770
Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22
Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo
@OncoAlert @myESMO #bcsm #ImmOnc
BCC 2021
The 17th St. Gallen International Breast Cancer Conference was held virtually this year due to the ongoing COVID-19 pandemic. Although the meeting was virtual, the programme was full of the latest data, ongoing controversies in the field, and updates on potential new treatments for breast cancer, culminating in the renowned St Gallen International Consensus on the Optimal Primary Treatment of Women with Breast Cancer 2021.
🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals
Watch: 👉http://ow.ly/LwxB50LQ3p0👈
@UKONSmember #UKONS2022 #Nursing #OncologyNursing
🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?
IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.
💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770
Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22
Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo
@OncoAlert @myESMO #bcsm #ImmOnc
VJOncology is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
